We are live on ! Find out more
DMKJ

David M. Knott Jr Portfolio holdings

AUM $189M Turnover 22.11%
1-Year Est. Return 67.72%
This Fund
S&P 500
This Quarter Est. Return
-2.49%
1 Year Est. Return
+67.72%
3 Year Est. Return
+169.37%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$168M
AUM Growth
-$47.9M
Cap. Flow
-$34.3M
Cap. Flow %
-20.4%
Top 10 Hldgs %
60.49%
Holding
95
New
8
Increased
17
Reduced
13
Closed
10
Avg Time Held
2.2 years
Top 10 Avg Time Held
1.3 years
Top 20 Avg Time Held
1.1 years

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.12M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$2.13M
3
RLMD icon
Relmada Therapeutics
RLMD
+$2.08M
4
ARDX icon
Ardelyx
ARDX
+$1.37M
5
TGTX icon
TG Therapeutics
TGTX
+$1.34M

Top Sells

Rank Stock Value
1
CLMT icon
Calumet Specialty Products
CLMT
+$44M
2
CPRX icon
Catalyst Pharmaceutical
CPRX
+$1.64M
3
TECX icon
Tectonic Therapeutic
TECX
+$1.54M
4
TVTX icon
Travere Therapeutics
TVTX
+$1.36M
5
BHVN icon
Biohaven
BHVN
+$1.25M

Sector Composition

Rank Sector Weight
1 Healthcare 53.57%
2 Financials 19.49%
3 Communication Services 15.66%
4 Miscellaneous 8.54%
5 Technology 1.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
GOOG icon
1
Alphabet (Google) Class C
GOOG
$4.2T
$26.2M 15.61%
91,420
– –
2021 Q4
17 quarters
APO icon
2
Apollo Global Management
APO
$67B
$25.1M 14.92%
225,000
– –
2021 Q4
17 quarters
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.21B
$9.86M 5.87%
422,000
+7,000
+2% +$152K
2024 Q1
8 quarters
BBIO icon
4
BridgeBio Pharma
BBIO
$12.7B
$6.68M 3.98%
90,000
+5,000
+6% +$362K
2025 Q2
3 quarters
PTGX icon
5
Protagonist Therapeutics
PTGX
$8.82B
$6.64M 3.95%
63,000
-10,000
-14% -$885K
2023 Q3
10 quarters
XERS icon
6
Xeris Biopharma Holdings
XERS
$1.78B
$6.15M 3.66%
1,060,000
+90,000
+9% +$597K
2023 Q4
9 quarters
JPM icon
7
JPMorgan Chase
JPM
$890B
$5.73M 3.41%
19,477
– –
2021 Q4
17 quarters
IOVA icon
8
Iovance Biotherapeutics
IOVA
$6.44B
$5.62M 3.34%
+1,600,000
New +$5.12M
2026 Q1
0 quarters
JAAA icon
9
Janus Henderson AAA CLO ETF
JAAA
$32.1B
$4.71M 2.8%
93,528
– –
2023 Q3
10 quarters
ALKS icon
10
Alkermes
ALKS
$6.56B
$4.24M 2.53%
120,000
+25,000
+26% +$776K
2025 Q2
3 quarters
TVTX icon
11
Travere Therapeutics
TVTX
$5.02B
$4.18M 2.49%
140,633
-45,367
-24% -$1.36M
2023 Q3
10 quarters
COGT icon
12
Cogent Biosciences
COGT
$4.88B
$4M 2.38%
104,000
+2,000
+2% +$73.9K
2025 Q4
1 quarter
VRDN icon
13
Viridian Therapeutics
VRDN
$2.08B
$3.54M 2.11%
181,000
+36,000
+25% +$1.07M
2024 Q4
5 quarters
AGIO icon
14
Agios Pharmaceuticals
AGIO
$1.85B
$3.15M 1.87%
93,058
+75,058
+417% +$2.13M
2025 Q4
1 quarter
RLMD icon
15
Relmada Therapeutics
RLMD
$346M
$3.06M 1.82%
+439,300
New +$2.08M
2026 Q1
0 quarters
TGTX icon
16
TG Therapeutics
TGTX
$8.32B
$2.99M 1.78%
90,001
+45,001
+100% +$1.34M
2025 Q4
1 quarter
CPRX icon
17
DELISTED
Catalyst Pharmaceutical
CPRX
$2.97M 1.77%
120,000
-69,000
-37% -$1.64M
2023 Q4
9 quarters
ACLX icon
18
DELISTED
Arcellx
ACLX
$2.23M 1.33%
19,433
-6,267
-24% -$553K
2025 Q1
4 quarters
XBI icon
19
State Street SPDR S&P Biotech ETF
XBI
$9.71B
$1.92M 1.14%
15,000
+2,000
+15% +$250K
2023 Q4
9 quarters
AB icon
20
AllianceBernstein
AB
$3.16B
$1.8M 1.07%
48,000
– –
2021 Q4
17 quarters
RCUS icon
21
Arcus Biosciences
RCUS
$2.87B
$1.75M 1.04%
81,241
-40,000
-33% -$864K
2025 Q1
4 quarters
DCGO icon
22
DocGo
DCGO
$26.9M
$1.68M 1%
2,670,850
– –
2021 Q4
17 quarters
HELP
23
Helus Pharma Inc. Common Stock
HELP
$758M
$1.68M 1%
350,000
+64,818
+23% +$419K
2024 Q4
5 quarters
CYTK icon
24
Cytokinetics
CYTK
$8.82B
$1.56M 0.93%
23,644
-10,356
-30% -$658K
2025 Q3
2 quarters
CNTA
25
DELISTED
Centessa Pharmaceuticals
CNTA
$1.55M 0.92%
39,000
+35,000
+875% +$895K
2025 Q4
1 quarter
1
2 3 4

Similar funds

SCA
Sander Capital Advisors Seattle, Washington $189M AUM 13.06% 1-Year Est. Return
FI
FWG Investments Lexington, Kentucky $189M AUM 18.47% 1-Year Est. Return
MFS
Madrid Financial Services Manhattan Beach, California $189M AUM 30.12% 1-Year Est. Return
FRA
FFG Retirement Advisors Centennial, Colorado $189M AUM 16.39% 1-Year Est. Return
CAM
Councilmark Asset Management Knoxville, Tennessee $189M AUM 26.93% 1-Year Est. Return
BAG
Bauman Advisory Group Las Vegas, Nevada $189M AUM
SHC
SALT Holding Corp Wilmington, Delaware $189M AUM 34.63% 1-Year Est. Return
HC
Hara Capital Bellevue, Washington $190M AUM 42.56% 1-Year Est. Return

David M. Knott Jr's Q1 2026 Portfolio in Review

As of Q1 2026, David M. Knott Jr held 95 positions worth $168M, down 22% from $216M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

David M. Knott Jr withdrew a net $34.3M in Q1 2026, closing 10 positions and reducing 13 holdings. Its most notable exit was Calumet Specialty Products, an estimated $44M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 41% a quarter earlier, followed by Financials and Communication Services.

Against the trend, David M. Knott Jr opened a new position in Iovance Biotherapeutics worth $5.62M.

  • David M. Knott Jr's largest Q1 2026 buy was Iovance Biotherapeutics: 1,600,000 shares worth $5.62M.
  • David M. Knott Jr added most to Agios Pharmaceuticals in Q1 2026, an estimated $2.13M increase.
  • David M. Knott Jr's biggest Q1 2026 reduction was Catalyst Pharmaceutical, cutting an estimated $1.64M.
  • David M. Knott Jr fully exited Calumet Specialty Products in Q1 2026, selling an estimated $44M.
  • David M. Knott Jr's ten largest holdings make up 60% of its $168M portfolio in Q1 2026.
  • David M. Knott Jr opened 8 new positions and closed 10 in Q1 2026.
  • David M. Knott Jr's portfolio value fell 22% quarter-over-quarter to $168M.

Based on David M. Knott Jr's 13F filing for Q1 2026, filed 14 May 2026.